Value
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 3.2 |
| P/S | 8.8 |
| EV/EBITDA | 3.9 |
| Fwd P/E | 1.5 |
| PEG | 7.5 |
| Analyst target | 9.0 |
- ▸Forward P/E: 68.1x
- ▸PEG: 0.91
PHAR · Why this verdict
Why Pharming Group (PHAR) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.5/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Pharming Group is a small-cap biotech below the minimum investable market cap of $1 billion, with declining revenue of -8% but an exceptional Piotroski score of 8 out of 9, strong free cash flow conversion, and analyst targets implying 128% upside if momentum recovers.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
At a market cap of $0.91 billion, Pharming falls below the $1 billion minimum investable threshold, placing it outside the standard investable universe regardless of other metrics. Warnings | Market cap rises above $1.0 billion within 12 months as the share price recovers toward analyst targets. | ↓Deteriorating |
| CounterSub-$1 billion biotechs can remain below the threshold indefinitely if revenue growth does not materialize or sentiment does not improve. | ||
Revenue is declining at -8% annually and the momentum score is 3.7 out of 10, below the minimum gate of 4.5, with the OBV showing volume distribution and the stock trading below its 200-day moving average. Momentum breakdown | Revenue returns to positive growth above 5% year-over-year and momentum score rises above 5.0 within 12 months. | ↑Improving |
| CounterThe 200-day moving average is still rising at +1.5% per month, suggesting the current price weakness may be a pullback within a broader uptrend rather than a structural downtrend. | ||
A Piotroski F-Score of 8 out of 9 and free cash flow conversion at 478% of net income are exceptional, indicating the company generates substantially more cash than its reported net income suggests. Quality breakdown | Piotroski score remains above 7 and free cash flow conversion stays above 200% of net income for 4 consecutive quarters. | ↑Improving |
| CounterHigh Piotroski scores in small biotechs can reflect accounting timing rather than durable cash generation, and the Rule of 40 score of 8 falls below the passing threshold. | ||
Analysts project a 168% price increase from current levels with a forward P/E of 44.1x and PEG ratio of 0.84, suggesting the market has not priced in expected earnings growth. Sentiment breakdown | Stock price rises above $20 within 12 months as earnings growth drives re-rating toward analyst targets. | ↑Improving |
| CounterLight analyst coverage of only 4 analysts dampens signal reliability, and the average earnings surprise history includes outliers that distort the consensus picture. | ||
At a market cap of $0.91 billion, Pharming falls below the $1 billion minimum investable threshold, placing it outside the standard investable universe regardless of other metrics.
↓DeterioratingWarnings
- Expectation
- Market cap rises above $1.0 billion within 12 months as the share price recovers toward analyst targets.
CounterSub-$1 billion biotechs can remain below the threshold indefinitely if revenue growth does not materialize or sentiment does not improve.
Revenue is declining at -8% annually and the momentum score is 3.7 out of 10, below the minimum gate of 4.5, with the OBV showing volume distribution and the stock trading below its 200-day moving average.
↑ImprovingMomentum breakdown
- Expectation
- Revenue returns to positive growth above 5% year-over-year and momentum score rises above 5.0 within 12 months.
CounterThe 200-day moving average is still rising at +1.5% per month, suggesting the current price weakness may be a pullback within a broader uptrend rather than a structural downtrend.
A Piotroski F-Score of 8 out of 9 and free cash flow conversion at 478% of net income are exceptional, indicating the company generates substantially more cash than its reported net income suggests.
↑ImprovingQuality breakdown
- Expectation
- Piotroski score remains above 7 and free cash flow conversion stays above 200% of net income for 4 consecutive quarters.
CounterHigh Piotroski scores in small biotechs can reflect accounting timing rather than durable cash generation, and the Rule of 40 score of 8 falls below the passing threshold.
Analysts project a 168% price increase from current levels with a forward P/E of 44.1x and PEG ratio of 0.84, suggesting the market has not priced in expected earnings growth.
↑ImprovingSentiment breakdown
- Expectation
- Stock price rises above $20 within 12 months as earnings growth drives re-rating toward analyst targets.
CounterLight analyst coverage of only 4 analysts dampens signal reliability, and the average earnings surprise history includes outliers that distort the consensus picture.
Per-dimension breakdown
Quality
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 2.9 |
| ROA | 4.2 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 3.1 |
| Current ratio | 9.8 |
| FCF quality | 10.0 |
| Moat | 7.1 |
| Rule of 40 | 5.5 |
| Piotroski F | 10.0 |
- ▸Excellent cash conversion: 176% FCF/NI
- ▸Strong Piotroski F-Score: 9/9
Growth
8.8/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 7.7 |
| EPS growth | 10.0 |
- ▸Strong growth: 21% YoY
Momentum
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.4 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 10.0 |
| vol acceleration | 8.1 |
- ▸Overbought bear rally (RSI 79)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -7.0%/30d — confirmed downtrend
- ▸Volume surge (2.1x avg) on up move
Sentiment
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.7 |
| Analyst rating | 7.1 |
| Price target | 10.0 |
- ▸Light analyst coverage (4.0) — signal dampened
- ▸Analyst upside: 180%
Insider
5.0/10data confidence 50%Peer rank
5.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.1 |
| quality rank | 6.8 |
| growth rank | 5.3 |
- ▸Superior ROE vs peers
Technical
0.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.1 |
| 52w position | 1.5 |
Risk (lower is worse)
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 10.0 |
| days to cover | 10.0 |
| volatility | 2.7 |
| beta | 10.0 |
| debt equity | 8.4 |
| news risk | 6.0 |
Catalyst
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| surprise avg | 0.0 |
| news activity | 8.0 |
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (7)
- MOMENTUM:7.8>=5.5
- ASYMMETRY:9.2>=1.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- DEATH_CROSS:momentum=7.8>=5.0 recovering
Reward-to-Risk
9.21
Upside
+138.2%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 79
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -42% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:7.8>=5.5. Top dim: Growth at 8.8; weakest: Technical at 0.5. No conviction either direction.
The strongest dimensions are Growth at 8.8, Risk (lower is worse) at 7.9, and Momentum at 7.8; the weakest are Technical at 0.5, Insider at 5.0, and Peer rank at 5.1. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 9.21 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Below Investable Market Cap
Trip ifMarket cap falls below $0.70 billion, indicating further deterioration in investability and increasing liquidity risk.
- P2Revenue Decline Momentum Weakness
Trip ifRevenue declines more than 15% year-over-year for 2 consecutive quarters, indicating accelerating business contraction.
- P3High Piotroski Cashflow Quality
Trip ifPiotroski F-Score drops below 6 or free cash flow falls below 50% of net income for 2 consecutive quarters.
- P4Analyst Upside Valuation
Trip ifAnalyst consensus price target falls below $18.00, reducing implied upside to less than 40% from current levels.